Currently, there is an ongoing phase two trial assessing the possible neurocognitive benefits from treatment with everolimus (NCT01289912). Future therapies involving the use of ATP-competitive mTOR inhibitors alone or in combinations with other drugs, such as estrogen antagonists, are being explored ...
Antipsychotic pharmacotherapy has been widely recommended as the standard of care for the treatment of acute schizophrenia and psychotic symptoms of other psychiatric disorders. However, there are growing concerns regarding antipsychotic-induced side effects, including weight gain, metabolic syndrome (MetS),...
Given that rapamycin is a starvation- or CR-mimetic42,61,62, its metabolic effects can be viewed as “starvation-mimicking side effects63." In a series of publications, I advanced the hypothesis that in animals (and humans) rapamycin can cause a reversible and benevolent condition, identical t...
Future directions for developing TOR-based therapy include assessing the long-term benefits of rapamycin as a candidate drug for heart failure patients, defining the dynamic activity of TOR, exploring the impacts of TOR signaling manipulation in different models ofcardiomyopathies, and elucidating the...
However, until now it was unknown whether the effects of late-life treatment are the same as that of lifelong treatment, or whether brief treatment at younger ages is sufficient for long-term benefits. Lead author of the study, Paula Juricic, PhD, an investigator in the department of Linda ...
If used daily, Rapamycin would have ZERO benefits and just a lot of harmful side effects. June 6, 2023: Announcement: New Drop-Down Section "Patient Bulletin Board"; This will be patient comments, questions, and important new papers patients find. My patients are extremely well-informed. I...
Antivirals: concentration possibly increased by atazanavir, boceprevir and lopinavir; concentration of both drugs increased with telaprevir, reduce dose of sirolimus; concomitant use with dasabuvir plus ombitasvir/paritaprevir/ritonavir is not recommended unless the benefits outweigh the risks, if used to...
Earlier experimental studies such as placement of external porous dacron stents [5] or perivascular application of decoy oligonucleotides [1, 2] have failed to translate into clinical benefits because of early graft thrombosis and poor efficacy, respectively. Gavin and colleagues [6] have recently ...
lifespan in mice3,11,12and enhance immune response in older people13,14. However, it is unknown whether the effects of late-life treatment are comparable to those of lifelong drug exposure, or whether brief treatment at younger ages is sufficient to gain the benefits of the chronic treatment...
successful effort to do so must identify and validate a particular, highly-impactful indication for which the benefits of using a microencapsulated rapamycin would be relatively irrefutable, and the effort must likewise develop corresponding methods and strategies for effectively and reliably addressing as...